The newly identified miR-320b/TRIAP1 pathway uncovers the molecular mechanisms underlying tumorigenesis and poor clinical outcomes of NPC and may facilitate the development of novel therapeutic strategies against NPC. Here, TRIAP1 is linked to nasopharyngeal carcinoma.